BRIEF-Novo Nordisk Says People With Type 2 Diabetes Who Were Increased To Semaglutide 2 Mg Were more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00

June 6 (Reuters) - Novo Nordisk A/S NOVOb.CO:

  • PEOPLE WITH TYPE 2 DIABETES WHO WERE INCREASED TO SEMAGLUTIDE 2 MG WERE AS LIKELY TO ACHIEVE AN HBA1C LESS THAN 7% AND MORE LIKELY TO ACHIEVE GREATER THAN 5% WEIGHT LOSS THAN THOSE WHO WERE SWITCHED TO TIRZEPATIDE, IN REAL-WORLD DATA

  • NOVO NORDISK - SEMAGLUTIDE 2 MG MATCHES TIRZEPATIDE FOR HBA1C <7% AND OUTPERFORMS FOR ≥5% WEIGHT LOSS AT 1 YEAR

  • 74.7% ON SEMAGLUTIDE 2 MG AND 75.1% ON TIRZEPATIDE ACHIEVE HBA1C <7% AT 1 YEAR

  • NOVO NORDISK - 60.5% ON SEMAGLUTIDE 2 MG AND 55.3% ON TIRZEPATIDE ACHIEVE ≥5% WEIGHT LOSS AT 1 YEAR

Source text: ID:nPn3wl63Za

Further company coverage: [NOVOb.CO]


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.